Integrin alpha 5 beta 1 Overview
Molecule Name
Integrin alpha-5/beta-1
Synonyms
Integrin alpha 5 beta 1,ITGA5&ITGB1
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs1
Highest Development StageApproved
Target Synonym
Integrin alpha5beta1
Background
Integrin alpha 5 beta 1 / Integrin α5β1, which is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development., is composed of α5 (ITGA5/CD49e) and β1 (ITGB1/CD29) subunits. Integrins are adhesion receptors that transmit bidirectional signals across the plasma membrane. The Integrin alpha 5 beta 1 and its primary extracellular matrix ligand fibronectin (Fn) are of great biological importance.
Integrin alpha 5 beta 1 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University | Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| VAX-014 | VAX-014 | Phase 1 Clinical | Vaxiion Therapeutics Llc | Solid tumours | Details |
| Integrin α5β1 therapy (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Cardiovascular Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd | 2005-09-12 | Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant | Details |